- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Submit a Manuscript
- Subscription Information
- Table of Contents
ISRN Vascular Medicine
Volume 2012 (2012), Article ID 785094, 6 pages
New Alternatives for Atherosclerosis Treatment Based on Immunomodulation
Center for Research and Biological Evaluations, Institute of Pharmacy and Food Sciences, University of Havana, 13600 Havana, Cuba
Received 12 July 2012; Accepted 13 August 2012
Academic Editors: A. Mugge and A. Paolicchi
Copyright © 2012 Livan Delgado Roche and Danay Alfonso Hernández. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. Mendis, P. Puska, and B. Norrving, Eds., Global Atlas on Cardiovascular Disease Prevention and Control, World Health Organization, Geneva, Switzerland, 2011.
- D. Steinberg, S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum, “Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity,” The New England Journal of Medicine, vol. 320, no. 14, pp. 915–924, 1989.
- D. Steinberg, “Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime,” Nature Medicine, vol. 8, no. 11, pp. 1211–1217, 2002.
- K. J. Williams and I. Tabas, “The response-to-retention hypothesis of early atherogenesis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, pp. 551–561, 1995.
- I. Tabas, K. J. Williams, and J. Borén, “Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications,” Circulation, vol. 116, no. 16, pp. 1832–1844, 2007.
- G. K. Hansson, “Immune and inflammatory mechanisms in the development of atherosclerosis,” British Heart Journal, vol. 69, no. 1, pp. S38–S41, 1993.
- R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999.
- P. K. Shah, “Apolipoprotein A-I/HDL infusion therapy for plaque stabilization-regression: a novel therapeutic approach,” Current Pharmaceutical Design, vol. 13, no. 10, pp. 1031–1038, 2007.
- C. Kishimoto, “Immunoglobulin therapy, myocardial diseases and atherosclerosis: recent experimental and clinical studies,” Current Cardiology Reviews, vol. 3, no. 1, pp. 15–21, 2007.
- D. M. Grosso, S. Ferderbar, A. C. B. A. Wanschel, M. H. Krieger, M. L. Higushi, and D. S. P. Abdalla, “Antibodies against electronegative LDL inhibit atherosclerosis in LDLr-/- mice,” Brazilian Journal of Medical and Biological Research, vol. 41, no. 12, pp. 1086–1092, 2008.
- H. Ait-Oufella, O. Herbin, J. D. Bouaziz et al., “B cell depletion reduces the development of atherosclerosis in mice,” Journal of Experimental Medicine, vol. 207, no. 8, pp. 1579–1587, 2010.
- K. L. L. Habets, G. H. M. Van Puijvelde, L. M. Van Duivenvoorde et al., “Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice,” Cardiovascular Research, vol. 85, no. 3, pp. 622–630, 2010.
- P. Dunér, F. To, K. Beckmann et al., “Immunization of apoE-/- mice with aldehyde-modified fibronectin inhibits the development of atherosclerosis,” Cardiovascular Research, vol. 91, no. 3, pp. 528–536, 2011.
- A. Hermansson, D. K. Johansson, D. F. J. Ketelhuth, J. Andersson, X. Zhou, and G. K. Hansson, “Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice,” Circulation, vol. 123, no. 10, pp. 1083–1091, 2011.
- Y. Soto, E. Acosta, L. Delgado, et al., “Antiatherosclerotic effect of an antibody that binds to extracellular matrix glycosaminoglycans,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, pp. 595–604, 2012.
- M. H. Davidson, K. Maki, D. Umporowicz, A. Wheeler, C. Rittershaus, and U. Ryan, “The safety and immunogenicity of a CETP vaccine in healthy adults,” Atherosclerosis, vol. 169, no. 1, pp. 113–120, 2003.
- S. Amir and C. J. Binder, “Experimental immunotherapeutic approaches for atherosclerosis,” Clinical Immunology, vol. 134, no. 1, pp. 66–79, 2010.
- Y. J. Geng and L. Jonasson, “Linking immunity to atherosclerosis: implications for vascular pharmacology -A tribute to Göran K. Hansson,” Vascular Pharmacology, vol. 56, pp. 29–33, 2012.
- C. W. Rittershaus, D. P. Miller, L. J. Thomas et al., “Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 9, pp. 2106–2112, 2000.
- Q. Gaofu, L. Jun, Y. Xin et al., “Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo,” Journal of Cardiovascular Pharmacology, vol. 45, no. 6, pp. 591–598, 2005.
- A. Schiopu, B. Frendéus, B. Jansson et al., “Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1-/-/low-density lipoprotein receptor-/- mice,” Journal of the American College of Cardiology, vol. 50, no. 24, pp. 2313–2318, 2007.
- R. Klingenberg, M. Lebens, A. Hermansson et al., “Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 5, pp. 946–952, 2010.
- R. Maron, G. Sukhova, A. M. Faria et al., “Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice,” Circulation, vol. 106, no. 13, pp. 1708–1715, 2002.
- G. H. M. Van Puijvelde, T. Van Es, E. J. A. Van Wanrooij et al., “Induction of oral tolerance to HSP60 or an HSP60-peptide activates t cell regulation and reduces atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 12, pp. 2677–2683, 2007.
- X. Zeng, J. Chen, Y. I. Miller, K. Javaherian, and K. S. Moulton, “Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis,” Journal of Lipid Research, vol. 46, no. 9, pp. 1849–1859, 2005.
- D. Mao, G. Kai, Q. Gaofu et al., “Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis,” Vaccine, vol. 24, no. 23, pp. 4942–4950, 2006.
- G. Qi, J. Li, S. Wang et al., “A chimeric peptide of intestinal trefoil factor containing cholesteryl ester transfer protein B cell epitope significantly inhibits atherosclerosis in rabbits after oral administration,” Peptides, vol. 32, no. 4, pp. 790–796, 2011.
- G. N. Fredrikson, I. Söderberg, M. Lindholm et al., “Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5, pp. 879–884, 2003.
- W. Palinski and J. L. Witztum, “Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis,” Journal of Internal Medicine, vol. 247, no. 3, pp. 371–380, 2000.
- P. X. Shaw, S. Hörkkö, S. Tsimikas et al., “Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 8, pp. 1333–1339, 2001.
- A. De Maio, “Heat shock proteins: facts, thoughts, and dreams,” Shock, vol. 11, no. 1, pp. 1–12, 1999.
- G. Caligiuri, A. Nicoletti, B. Poirierand, and G. K. Hansson, “Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice,” Journal of Clinical Investigation, vol. 109, no. 6, pp. 745–753, 2002.
- S. Tsimikas, E. S. Brilakis, R. J. Lennon et al., “Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events,” Journal of Lipid Research, vol. 48, no. 2, pp. 425–433, 2007.
- M. P. W. Moos, N. John, R. Gräbner et al., “The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 11, pp. 2386–2391, 2005.
- M. C. Aubry, D. L. Riehle, W. D. Edwards et al., “B-Lymphocytes in plaque and adventitia of coronary arteries in two patients with rheumatoid arthritis and coronary atherosclerosis: preliminary observations,” Cardiovascular Pathology, vol. 13, no. 4, pp. 233–236, 2004.
- P. J. Little, M. L. Ballinger, and N. Osman, “Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis,” Vascular Health and Risk Management, vol. 3, no. 1, pp. 117–124, 2007.
- W. Halfter, S. Dong, B. Schurer, and G. J. Cole, “Collagen XVIII is a basement membrane heparan sulfate proteoglycan,” Journal of Biological Chemistry, vol. 273, no. 39, pp. 25404–25412, 1998.
- S. Dong, G. J. Cole, and W. Halfter, “Expression of collagen XVIII and localization of its glycosaminoglycan attachment sites,” Journal of Biological Chemistry, vol. 278, no. 3, pp. 1700–1707, 2003.
- K. S. Moulton, B. R. Olsen, S. Sonn, N. Fukai, D. Zurakowski, and X. Zeng, “Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis,” Circulation, vol. 110, no. 10, pp. 1330–1336, 2004.
- L. D. Roche, E. A. Medina, Y. Hernández-Matos, M. A. Bécquer Viart, A. M. Vázquez López, and E. Fernández-Sánchez, “High levels of lipid peroxidation induced by Lipofundin administration correlate with atherosclerotic lesions in rabbits,” Pharmacologyonline, vol. 3, pp. 727–736, 2010.
- L. Delgado, E. Acosta, A. Fraga, et al., “Lipofundin-induced hyperlipidemia promotes oxidative stress and atherosclerotic lesions in New Zealand white rabbits,” International Journal of Vascular Medicine, vol. 2012, pp. 1–7, 2011.
- A. S. Bourinbaiar and V. Jirathitikal, “Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices,” Vaccine, vol. 28, no. 15, pp. 2763–2768, 2010.